Recent discussions on X about Insulet Corporation (PODD) have centered around the company's stock performance and analyst ratings, with a particular focus on the consensus 'Moderate Buy' rating from brokerages as reported on financial news platforms. Many users on the platform have expressed curiosity about the implications of this rating, noting that a significant majority of analysts are leaning toward a positive outlook. The chatter reflects a keen interest in how this might influence investor confidence in the medical device sector.
Additionally, posts on X have highlighted recent institutional activity, such as acquisitions and reductions in holdings by various financial entities, sparking debates over the stock's future trajectory. Some users are pointing to these movements as potential signals of shifting market dynamics for Insulet Corporation, while others remain cautious about drawing firm conclusions. The conversation continues to evolve as more investors weigh in with their perspectives on the company’s strategic direction.
Note: This discussion summary was generated from an AI condensation of post data.
Insulet Corporation Insider Trading Activity
Insulet Corporation insiders have traded $PODD stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $PODD stock by insiders over the last 6 months:
- JOHN W. KAPPLES (SVP and General Counsel) sold 5,278 shares for an estimated $1,680,884
- ERIC BENJAMIN (EVP, CPXO) sold 3,001 shares for an estimated $960,320
- PREM SINGH (SVP, Global Operations) sold 2,327 shares for an estimated $698,216
- WAYNE A.I. FREDERICK sold 1,825 shares for an estimated $501,875
- DAN MANEA (SVP, Chief HR Officer) sold 1,300 shares for an estimated $390,065
- LUCIANA BORIO sold 481 shares for an estimated $147,056
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Insulet Corporation Hedge Fund Activity
We have seen 378 institutional investors add shares of Insulet Corporation stock to their portfolio, and 303 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL RESEARCH GLOBAL INVESTORS removed 1,369,765 shares (-18.4%) from their portfolio in Q1 2025, for an estimated $359,713,986
- GAMMA INVESTING LLC removed 661,223 shares (-99.6%) from their portfolio in Q2 2025, for an estimated $207,743,042
- AMERIPRISE FINANCIAL INC removed 641,215 shares (-50.4%) from their portfolio in Q1 2025, for an estimated $168,389,471
- CITADEL ADVISORS LLC removed 585,155 shares (-80.3%) from their portfolio in Q1 2025, for an estimated $153,667,554
- MACQUARIE GROUP LTD added 406,038 shares (+58.8%) to their portfolio in Q1 2025, for an estimated $106,629,639
- FISHER ASSET MANAGEMENT, LLC removed 331,272 shares (-87.7%) from their portfolio in Q1 2025, for an estimated $86,995,339
- AMERICAN CENTURY COMPANIES INC added 297,734 shares (+34.8%) to their portfolio in Q1 2025, for an estimated $78,187,925
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Insulet Corporation Analyst Ratings
Wall Street analysts have issued reports on $PODD in the last several months. We have seen 10 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 06/16/2025
- Goldman Sachs issued a "Buy" rating on 05/30/2025
- Raymond James issued a "Outperform" rating on 05/27/2025
- Citigroup issued a "Buy" rating on 05/22/2025
- Wolfe Research issued a "Outperform" rating on 05/13/2025
- Oppenheimer issued a "Outperform" rating on 05/09/2025
- RBC Capital issued a "Outperform" rating on 03/06/2025
To track analyst ratings and price targets for Insulet Corporation, check out Quiver Quantitative's $PODD forecast page.
Insulet Corporation Price Targets
Multiple analysts have issued price targets for $PODD recently. We have seen 12 analysts offer price targets for $PODD in the last 6 months, with a median target of $332.0.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $365.0 on 06/16/2025
- David Roman from Goldman Sachs set a target price of $380.0 on 05/30/2025
- Jayson Bedford from Raymond James set a target price of $360.0 on 05/27/2025
- Joanne Wuensch from Citigroup set a target price of $380.0 on 05/22/2025
- Mike Polark from Wolfe Research set a target price of $350.0 on 05/13/2025
- Steven Lichtman from Oppenheimer set a target price of $324.0 on 05/09/2025
- Matt Miksic from Barclays set a target price of $266.0 on 04/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
